CD4+CD25+ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells

Vaccine

Volumn 29, Issue 15, 2011, Pages 2649-2652

  Navarrete, Ana Maria ^a,b,c   Delignat, Sandrine ^a,b,c   Teillaud, Jean Luc ^a,b,c   Kaveri, Srini V ^a,b,c,d   Lacroix Desmazes, Sébastien ^a,b,c,d   Bayry, Jagadeesh ^a,b,c,d,e  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d National Institute of Immunohaemotology   (India)

^e INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

CD4+CD25+ regulatory T cells; Dendritic cells; Endocytic receptors; Vaccines

Indexed keywords

ANTIGEN; FC RECEPTOR; FC RECEPTOR IIB; IMMUNOGLOBULIN G;

ARTICLE; CD4+ CD25+ T LYMPHOCYTE; DENDRITIC CELL; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PINOCYTOSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; VACCINATION;

CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; CELLS, CULTURED; DENDRITIC CELLS; ENDOCYTOSIS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LECTINS, C-TYPE; MANNOSE-BINDING LECTINS; RECEPTORS, CELL SURFACE; RECEPTORS, IGG; T-LYMPHOCYTES, REGULATORY;

EID: 79952242603     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.095     Document Type: Article

References (37)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(March (6673)):245-252.
2. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10(7):490-500.
3. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30(5):636-645.
4. Andre S., Tough D.F., Lacroix-Desmazes S., Kaveri S.V., Bayry J. Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am J Pathol 2009, 174(5):1575-1587.
5. Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008, 9(3):239-244.
6. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322(5899):271-275.
7. Shevach E.M. Immunology. Regulating suppression. Science 2008, 322(5899):202-203.
8. Bayry J. Autoimmunity: CTLA-4: a key protein in autoimmunity. Nat Rev Rheumatol 2009, 5(5):244-245.
9. Haque A., Best S.E., Amante F.H., Mustafah S., Desbarrieres L., de Labastida F., et al. CD4 natural regulatory T cells prevent experimental cerebral malaria via CTLA-4 when expanded in vivo. PLoS Pathog 2010, 6(12):e1001221.
10. Shimizu J., Yamazaki S., Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999, 163(10):5211-5218.
11. Toka F.N., Suvas S., Rouse B.T. CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1. J Virol 2004, 78(23):13082-13089.
12. van't Land B., Schijf M., van Esch B.C., van Bergenhenegouwen J., Bastiaans J., Schouten B., et al. Regulatory T-cells have a prominent role in the immune modulated vaccine response by specific oligosaccharides. Vaccine 2010, 28(35):5711-5717.
13. Gray A., de la Luz Garcia-Hernandez M., van West M., Kanodia S., Hubby B., Kast W.M. Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages. Vaccine 2009, 27(Suppl. 6):G52-G59.
14. Surls J., Nazarov-Stoica C., Kehl M., Casares S., Brumeanu T.D. Differential effect of CD4+Foxp3+ T-regulatory cells on the B and T helper cell responses to influenza virus vaccination. Vaccine 2010, 28(45):7319-7330.
15. Klages K., Mayer C.T., Lahl K., Loddenkemper C., Teng M.W., Ngiow S.F., et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010, 70(20):7788-7799.
16. Guermonprez P., Valladeau J., Zitvogel L., Thery C., Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002, 20:621-667.
17. de Jong M.A., Geijtenbeek T.B. Langerhans cells in innate defense against pathogens. Trends Immunol 2010, 31(12):452-459.
18. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008, 8(1):34-47.
19. Houot R., Perrot I., Garcia E., Durand I., Lebecque S. Human CD4+CD25 high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol 2006, 176(9):5293-5298.
20. Veldhoen M., Moncrieffe H., Hocking R.J., Atkins C.J., Stockinger B. Modulation of dendritic cell function by naive and regulatory CD4+ T cells. J Immunol 2006, 176(10):6202-6210.
21. Bayry J., Triebel F., Kaveri S.V., Tough D.F. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol 2007, 178(7):4184-4193.
22. Onishi Y., Fehervari Z., Yamaguchi T., Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A 2008, 105(29):10113-10118.
23. Navarrete A.M., Meslier Y., Teyssandier M., Andre S., Delignat S., Triebel F., et al. CD4+CD25+ regulatory T cells modulate human dendritic cell chemokines via multiple mechanisms. Arthritis Rheum 2009, 60(9):2848-2849.
24. Boruchov A.M., Heller G., Veri M.C., Bonvini E., Ravetch J.V., Young J.W. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005, 115(10):2914-2923.
25. Tang H.L., Cyster J.G. Chemokine up-regulation and activated T cell attraction by maturing dendritic cells. Science 1999, 284:819-822.
26. Iellem A., Mariani M., Lang R., Recalde H., Panina-Bordignon P., Sinigaglia F., et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001, 194(6):847-853.
27. Lindqvist M., Navabi N., Jansson M., Samuelson E., Sjoling A., Orndal C., et al. Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice. Vaccine 2009, 28(1):270-278.
28. Aimanianda V., Haensler J., Lacroix-Desmazes S., Kaveri S.V., Bayry J. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci 2009, 30(6):287-295.
29. Tritto E., Mosca F., De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009, 27(25-26):3331-3334.
30. Taguchi O., Takahashi T. Administration of anti-interleukin-2 receptor alpha antibody in vivo induces localized autoimmune disease. Eur J Immunol 1996, 26:1608-1612.
31. Bayry J., Flower D.R., Tough D.F., Kaveri S.V. From 'perfect mix' to 'potion magique'-regulatory T cells and anti-inflammatory cytokines as adjuvant targets. Nat Rev Microbiol 2008, 6(1):C1.
32. Bayry J., Tchilian E.Z., Davies M.N., Forbes E.K., Draper S.J., Kaveri S.V., et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A 2008, 105(29):10221-10226.
33. Davies M.N., Bayry J., Tchilian E.Z., Vani J., Shaila M.S., Forbes E.K., et al. Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLoS One 2009, 4(11):e8084.
34. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10(9):942-949.
35. Kang S., Xie J., Ma S., Liao W., Zhang J., Luo R. Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets. Immunobiology 2010, 215(2):153-162.
36. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010, 107(9):4275-4280.
37. Sorensen M.R., Holst P.J., Steffensen M.A., Christensen J.P., Thomsen A.R. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 2010, 28(41):6757-6764.